| Pharmaceutical Information |
| Drug Name |
Ribociclib |
| Drug ID |
BADD_D02483 |
| Description |
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. |
| Indications and Usage |
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EF02 |
| DrugBank ID |
DB11730
|
| KEGG ID |
D10883
|
| MeSH ID |
C000589651
|
| PubChem ID |
44631912
|
| TTD Drug ID |
D08MXP
|
| NDC Product Code |
0078-0860; 0078-0874; 0078-0867 |
| UNII |
TK8ERE8P56
|
| Synonyms |
ribociclib | LEE011 | Kisqali |
|
| Chemical Information |
| Molecular Formula |
C23H30N8O |
| CAS Registry Number |
1211441-98-3 |
| SMILES |
CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
